Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / CAMP4 Therapeutics Corporation

Clinicaltrial registered13 Nov 2026

CAMP4 Therapeutics Corporation

13 Nov 2026: Trial registered · Study of CMP-002 in Participants With SYNGAP1-Related Disorder. Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
13 Nov 2026
Title
Study of CMP-002 in Participants With SYNGAP1-Related Disorder
Conditions
Nervous System Disease
Phase
Phase 1, Phase 2
Study Type
Interventional
Status
Not Yet Recruiting
Countries
Argentina
Country
Argentina
Reference
NCT07935135
Location
Argentina
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at CAMP4 Therapeutics Corporation

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

More from Argentina

New Clinical Trials

See all

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.